Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

     

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2016. Fulvestrant purchased from Selleck.

  • A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M1nEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO4NU4{NTFyMECgcm0> M{XHUFQ5KGh? MkfNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M36xPVI1QTd7Mkm0
MCF-7/LTED M1TvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHiSotDOS5|LUGwNFAhdk1? NF\kOJM1QCCq NGLlbWZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn7DNlQ6Pzl{OUS=
HCC1428 M1LpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPaNU4{NTFyMECgcm0> MUe0PEBp NILJeodqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWqyOFk4QTJ7NB?=
HCC1428/LTED MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrVRo8yNjNvMUCwNEBvVQ>? NHzMZmE1QCCq MmDhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYX4VWk1OjR7N{myPVQ>
LCC1 NHLhNZpHfW6ldHnvckBCe3OjeR?= MkK2NVAxKG6P MUG0PE0yPDRiaB?= NIrhWJNi[3SrdnH0[ZMhXVCUIIPp[45idGmwZx?= NWXCfpVSOjR6NUiyO|c>
LCC9 NGTKT5FHfW6ldHnvckBCe3OjeR?= NI\SRmsyODBibl2= MUO0PE0yPDRiaB?= NWe1UGhk[WO2aY\heIV{KFWSUjDzbYdv[Wyrbne= MkOwNlQ5PTh{N{e=
MCF-7  M3:0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\mRlExOCCwTR?= MnG5OUBl NIK5d4hqdmirYnn0d{Bk\WyuIHfyc5d1cCC2bzCxNQ+9jQ>? MlrONlQ5OTl3NUC=
mesangial  MYnGeY5kfGmxbjDBd5NigQ>? M1K1SFAvOS1zMECgcm0> M1S0OFQ5KGh? M1;qWpN2eHC{ZYPz[ZMhXEeILd8yNU1qdmS3Y3XkJJR6eGViSW[gZ49tdGGpZX6= M3fYOFI1Pzl|NkO5
Mesangial M4XmdWZ2dmO2aX;uJGF{e2G7 MlT5NE4yNTFyMDDuUS=> MkjrNE42KGh? MWnpcohq[mm2czDUS2Yu|rJzLXnu[JVk\WRiU33h[FIheGixc4Doc5J6dGG2aX;uJJZq[SCJUFXS NUXqe3pQOjR5OUO2N|k>
ER+ MCF-7/2a MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEC0JO69VQ>? NGPySXoyPTN{NEi4OC=>
ER+ MCF-7 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqyNFAhcA>? M3judWlEPTB;MD6yNUBvVQ>? MlLWNVU{OjR6OES=
MCF-7  MnS5SpVv[3Srb36gRZN{[Xl? MkPQNVDDqG6PwrC= Mn7PO|IhcA>? MmnZdoV3\XK|ZYOgeIhmKGW|dILv[4VvKGWoZnXjeEhKSzVyIEGuPUDEnyBzMPMIllkhVSl? M2fEbVI1QTB6NkWy
MCF-7  NUjHNnd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzTWM2OMLib3[gZZBxem:6aX3heIVtgSB{IH7N M3LuOVI{PDR6M{S2
H1975  MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SwTFPDqM7:TR?= MkTMNUBu NVjnU4pmcW6lcnXhd4V{KHSqZTDn[YZqfGmwaXKgd4Vve2m2aY\peJkhd2ZiSEG5O|Uh[2WubIRCpC=> M{PvN|I1OjZ6OEGw
H1975 MXPGeY5kfGmxbjDBd5NigQ>? NVHCVGNkO8LizszN NILLTVUyKG1? NUjIO4ZVfXC{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGxmfC15Yx?= M3LkclI1OjZ6OEGw
MCF-7  MnvTSpVv[3Srb36gRZN{[Xl? NWrnO|d1OTBy4pEJcm3DqA>? M1fNVFczKGh? M3m5[pJmfmW{c3XzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDFNuKhcW5iY3XscEBqdn[jc3nvci=> NX\tVFFOOjN7M{[3O|M>
MCF-7  Mo[5SpVv[3Srb36gRZN{[Xl? NWOxR2N[OTBy4pEJcm3DqA>? NEHQNlkzPC92ODDo MVrmZYNqdGm2YYTld{Bqdn[jc3nvckB1cHKxdXfoJG1OWHNpIH3v[JVt[XSrb36= MYmyN|k{Pjd5Mx?=
BT474-tet-shMED1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m0SFAvOS13IN88US=> NV24SGZFPyCm NVPkWlJRcW6lcnXhd4V{KCuGb4igbY5lfWOnZDDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWCyN|k{PjJ|NB?=
ZR75-1-tet-shMED1  NIHQV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjEbGUxNjFvNTFOwG0> MYG3JIQ> MkPDbY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIq2Rm8zOzl|NkKzOC=>
MCF-7-tet-shMED1 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fHbVAvOS13IN88US=> NWTSZ2tUPyCm Mlr1bY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1LYW|I{QTN4MkO0
HepG2  MnjDSpVv[3Srb36gRZN{[Xl? M4LTWVAvODFvMUCg{txO MkD4NVghcMLi NInxcFdi[3SrdnH0[ZMhfGinIFXSSU1u\WSrYYTl[EB1emGwc3PybZB1cW:wIH;mJGFHOkWU MWCyN|c{OzF6OB?=
MCF-7L  NHPZZYRHfW6ldHnvckBCe3OjeR?= MWGxNFAhdk4EoB?= M{XhZVExKG2rbj:yOEBpNzR6IHi= MWPy[ZN2dHS|IHnuJGVITlJuIFjFVlIh[W6mIFjFVlMheGixc4Doc5J6dGG2aX;uJIF1KHC{b3zvcodm\CCneIDvd5Vz\Q>? NGrIUm4zOzZ6NkSxOi=>
MCF-7L  M3HKS2Z2dmO2aX;uJGF{e2G7 M3vSWFExOCCwTdMg NFq3VJA1QCCq NFy5[YJqdmS3Y3XzJJVxemWpdXzheIlwdiCxZjDtVm5CKG:oIFXHSnIhdGmpYX7kJGhDNUWJRh?= NV65SVFiOjN4OE[0NVY>
MCF-7L NUXEOWF{TnWwY4Tpc44hSXO|YYm= NHfReWQyODBibl5CpC=> M3vhRVQ5KGh? NWXtW5R4cW6mdXPld{BGT0[UIH\hcYltgSCvZX3i[ZIh[WO2aY\heIlwdiC{ZYH1bZJm\CCHUh?= MYiyN|Y5PjRzNh?=
C4-12  MUjGeY5kfGmxbjDBd5NigQ>? MmXKNVAxKG6PwrC= NH7seZg1QCCq MmXQbY5lfWOnczDFS2ZTKG[jbXnsfUBu\W2kZYKgZYN1cX[jdHnvckBz\XG3aYLl[EBGWg>? MoHONlM3QDZ2MU[=
MCF-7L MmX6SpVv[3Srb36gRZN{[Xl? M1LKbFExOCCwTdMg NYm0V2t[OjRiaB?= M4P1Volv\HWlZYOgSWdHWiCyaH;zdIhwenmuYYTpc44hemWzdXny[YQhUEJvRVfGJIZ2dmO2aX;u NHvvSHYzOzZ6NkSxOi=>
MMQ  NWrtSFBYTnWwY4Tpc44hSXO|YYm= MnmyNE03OjVibl2= MUS3NkBp NX\lU29V\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[g[ZN1em:pZX6gdoVk\XC2b4Kt{tEhMEWUzsGp NED1XYUzOzV{M{O1Oy=>
H1975  NGfiUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\DNE4{OTJ3LUGwJO69VQ>? M4m4T|Yh\A>? MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn3SNlM{QTl7NUe=
H1975  MljkRZBweHSxc3nzJGF{e2G7 NI\vWW8zODBibl2= NG\uR4Y4OiCq M1z2ZYVvcGGwY3XzJIVzdG:2aX7pZkBqdmS3Y3XkJIFxd3C2b4Ppdy=> M1;TSVI{Ozl7OUW3
MCF-7  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHYNVAwOTByL{GwNFAhdk1? NVPZVIJyOi92L{[g[C=> MnPGSG1UVw>? NEnMRXpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy Mn3ZNlM{OTN3ME[=
MCF-7  Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWxNFAhdk1? MlrjOEBl MYfEUXNQ MWLpcoR2[2W|IHGgbIlocGW{IIDyc5BwenSrb36gc4Yh[2WubIOgbY4hfGinIFexJJBp[XOnwrC= NF\DNZUzOzNzM{WwOi=>
MLO-Y4  MVfGeY5kfGmxbjDBd5NigQ>? M2PGNlHDqM7:TR?= Ml\KNUBp MnXabY5pcWKrdIOgSVIucW6mdXPl[EBEgDR|IHX4dJJme3Orb36= MWWyN|I1PzB3Nx?=
MCF-7 M4DhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmraNVAxKG6P MmTlOFghcA>? MWHhZpJw\2G2ZYOgeIhmKHC{b3zp[oVz[XSrdnWg[YZn\WO2IH;mJI1w\GW{YYTlJI5qfHKxc3H0bZZmKHO2cnXzdy=> NYC2N4w4OjN{MU[3OFQ>
TG1-1  NY\lNpF4TnWwY4Tpc44hSXO|YYm= Ml7ENeKh|ryP M1T1b|I1KGh? MkDzZYJzd2ejdHXzJGUzyqCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBJUUZvMd8x MW[yN|A5QDZyNx?=
TG1-1  NHXhVIZHfW6ldHnvckBCe3OjeR?= MmrRNeKh|ryP NU\NNYRuOjRiaB?= NYTYNW1j[WK{b3fheIV{KEV{wrDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCSSUPL M2S0fFI{ODh6NkC3
MCF7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNFAhdk1? M2XkXVQ5KGh? MoT4cIVi\HNidH:gZUB{cW2rbHHyJIxwe3NiaX6gd5Vzfmm4YXygZZMhf2m2aDDkc5hwenWkaXPpckBidG:wZR?= NU\zbm1DOjNyN{eyOFk>
MCF7 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNFAhdk1? MX20PEBp MWTlcohidmOnczDueZRtcW5vbXXkbYF1\WRiY3XscEBl\WG2aB?= M1zxUlI{ODd5MkS5
MCF-7  MonrSpVv[3Srb36gRZN{[Xl? MVy2JIg> MX;EUXNQ M1HnTIF1fGWwdXH0[ZMhfGinIH\seYRqd3ixbnnsMUBweiCoZX7o[ZhidWmmLXnu[JVk\WRiaX7jdoVie2ViaX6gcYlTNTJzIHX4dJJme3Orb36= NUTO[nE5OjNyNUKwN|Y>
MCF-7 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jmU|ExOCCwTT:xJO69VQ>? M{LPN|Uh\A>? M4\jUIlvcGmkaYTzJJRp\SC|dHnteYxifGmxbjDv[kAyP87{LXXzeJJi\GmxbB?= M1exU|IzQTh{N{[1
MCF-7 NGHmOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC4c|QyODBibl2= MnfCOUBl MkHLbY5pcWKrdIOgeIhmKHO2aX31cIF1cW:wIH;mJIZ2e2G{aXXsbY4hUA>? MUKyNlk5Ojd4NR?=
1471.1 MVTGeY5kfGmxbjDBd5NigQ>? MnHuNVAxKG6P NIDYZoYyKGh? NXfKNIJsTXSRSNMg MkHYeIFs\XNib36gZUBxfW6ldHH0[UB{fGGrbnnu[{Bx[XS2ZYLu M{HsV|IzQDZ7MUC2
MCF-7 NXnkcZZ6TnWwY4Tpc44hSXO|YYm= MXexNFAhdk1? MYqxJIg> NGnpVJFGfE:KwrC= NE\NW3N1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NETSXYgzOjh4OUGwOi=>
HeLa MWrGeY5kfGmxbjDBd5NigQ>? NXrWZ2V[OTByIH7N MWGxJIg> NHTFZmJGfE:KwrC= NUfabVNOfGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv Mki1NlI5PjlzME[=
COS-7  NILRS25HfW6ldHnvckBCe3OjeR?= NWnkZ3dtOTByIH7N MoPiNUBp NHHjXFNGfE:KwrC= M2O5N5Ric2W|IH;uJIEheHWwY4TheIUhe3SjaX7pcocheGG2dHXyci=> NXL3[ZByOjJ6NkmxNFY>
BG1L-OHTLT  MlrkSpVv[3Srb36gRZN{[Xl? MYWxNOKhdk1? NGTl[5ozPMLiaNMg NVTFeHdqcW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u NXLwfWhEOjJ4NUK1OVg>
BG1L-ICILT M132dWZ2dmO2aX;uJGF{e2G7 NF[ybm0yOMLibl2= NITP[GMzPMLiaNMg NEKyT3pqdmirYnn0d{BGWs7zIHX4dJJme3Orb36= MmDiNlI3PTJ3NUi=
PC-9 NHzpWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nuSlAvODB|LUOwJO69VQ>? NEDEcI41QCCq MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1\wZ|IzPTZyNkO0
H1650 NUXudmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fmU|AvODB|LUOwJO69VQ>? NUHHWo5OPDhiaB?= NIH4cY9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWniTFNnOjJ3NkC2N|Q>
H1975 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPh[ZBzOC5yMEOtN|Ah|ryP MofPOFghcA>? M4f3[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVjXcVFYOjJ3NkC2N|Q>
H1975 MV\GeY5kfGmxbjDBd5NigQ>? MVGzxsDPxE1? MUKzJIg> M3zxbIFjem:pYYTld{B1cGVicHjvd5Bpdy2HR1\SJIlv\HWldHnvckBjgSCnc4Tyc4dmdg>? M1\CUVIzPTZyNkO0
H1975 MkPDSpVv[3Srb36gRZN{[Xl? NGfnZ28{yqEQvF2= MVy3JIQ> NWLY[IZTcW6mdXPld{BGT0[UIHX4dJJme3Orb36= NVrDb5hJOjJ3NkC2N|Q>
HTR-8 Mmr5SpVv[3Srb36gRZN{[Xl? MkTLNeKh|ryP NV74W25WOS12ODDo M{nLVoRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B MnnDNlI{QDNzMUG=
JEG-3 NUC0U2x[TnWwY4Tpc44hSXO|YYm= NUi4dWJtOcLizszN NGfnbW4yNTR6IHi= NVrC[Wt7\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTWdHSlB5IH3SUmE> NWj3XZJ3OjJ|OEOxNVE>
Huh7 MWPGeY5kfGmxbjDBd5NigQ>? NVHYVpB7PTEEoN88US=> M1vLSFQ5KGh? M4DISIlvcGmkaYTzJIdmdmm|dHXpck1u\WSrYYTl[EBRV05zIITyZY5{[WO2aY\heIlwdg>? NX:ydJpZOjJ|MESyPVY>
201T NXHGZ5drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOwOUDPxE1? NXHWUnU1PzJiaB?= NID2RmJqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhidnHu[IV1[W6rYh?= M33WXVIzOjV6NEe2
A549  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7sOoU2KM7:TR?= NUHmboVkPzJiaB?= NIfrXopqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhidnHu[IV1[W6rYh?= NH7ZUXczOjJ3OES3Oi=>
MCF-7 MYrGeY5kfGmxbjDBd5NigQ>? MnTDNeKh|ryP NGjhW2UzPCCqwrC= M174coRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? NXPHeGJzOjJyNEmzNVY>
HCC-1428 NI[5bpNHfW6ldHnvckBCe3OjeR?= Mn3lNeKh|ryP NGf4SW8zPCCqwrC= NW\3NmRl\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NYDTeZJQOjJyNEmzNVY>
MDA-361 NV70R2NpTnWwY4Tpc44hSXO|YYm= NWLQTVJoOcLizszN NFrPTpAzPCCqwrC= MkHo[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh M4rlXFIzODR7M{G2
ZR75-1 M4LHTGZ2dmO2aX;uJGF{e2G7 NELnVmcyyqEQvF2= NE\BVYYzPCCqwrC= M3\iXIRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? NUHN[Hl3OjJyNEmzNVY>
MCF-7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXGNeKh|ryP NXzDRpg{PS1zMDDk NEjqbYp{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? NH\RZ4UzOjB2OUOxOi=>
HCC-1428 NGe2WoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXT4p5OcLizszN MnXtOU0yOCCm NWT4RYl3e3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w NI\sb4ozOjB2OUOxOi=>
MDA-361 M4TZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\LNeKh|ryP MoHUOU0yOCCm NIXyfVV{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? NWDSTHJxOjJyNEmzNVY>
ZR75-1 NYfSdZNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnMNeKh|ryP MX61MVExKGR? NWnUXXVDe3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w MmPFNlIxPDl|MU[=
MCF-7/AC-1 NWjuPGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XES|AuOC5{IN88US=> NVfsXHh1PiCm MoPxbY5pcWKrdIOgZ4VtdCCpcn;3eIghdW:mZYP0cJk> MnWzNlIxPDJ5OUK=
MCF7 M2rDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjTSYcyOCEEtV2= MWe0PEBp MWjpcoR2[2W|IHPlcIwhcW6qaXLpeIlwdiC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkh\mmkcn;icIF{fHN? NU\SSWJjOjJyNEG4PFc>
MMQ M2P5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInvN5kxNTZ{NTDuUS=> Mlf1O|IhcA>? M3nyWJBzd2S3Y3XzJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd28EoB?= MV6yNlAyPTFyMR?=
MMQ NF3KbVJHfW6ldHnvckBCe3OjeR?= M1PjRVAuPjJ3IH7N NIHYZoo4OiCq MXHwdo9lfWOnczDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSsJIRwe2VvZHXw[Y5l\W62IILl[JVkfGmxbjDpckBRWkxic3XjdoV1cW:w MYWyNlAyPTFyMR?=
MCF7 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XIcVAuOSEQvF2= M3y1elI1NTF{MDDo M17vdIlvcGmkaYTzJJRp\SCpcn;3eIghd2ZiTVPGO{1[Si1zwrC= NGTUNI4zOTh4M{K1PC=>
HepG2 M{Hrb2Fxd3C2b4Ppd{BCe3OjeR?= Mli4NE4yyqEQvF2= MY[yOEBp MlyyZYJwdGm|aHXzJJRp\SCnc4Tyc4dmdi2rbnT1Z4VlKHWyLYLl[5Vt[XSrb36gc4Yh[XCxQVmgZY5lKGGyb12= NUjxd41LOjF6MU[yN|M>
MCF7–iFR3 NIC5dpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHl[HM1OjBvMUCwJI5O NX\mWnpkQTZiaB?= MYPlcohidmOnczDBVE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NXj4VJdYOjF5OUK4PFk>
MCF7S MlLSSpVv[3Srb36gRZN{[Xl? M3nXflHDqM7:TR?= NWHQ[Il4PDhiaB?= Mn\t[I94dnKnZ4XsZZRmeyCxdnXyZYxtKEWUzsGgdJJwfGWrbjDs[ZZmdHN? NHj1WmozOTV|M{G5OS=>
MCF7 MorvSpVv[3Srb36gRZN{[Xl? NGjPc3YyyqEQvF2= NYqwTXFZPDhiaB?= NFjIO4xld3ewcnXneYxifGW|IH;2[ZJidGxiRWNOtUBxem:2ZXnuJIxmfmWucx?= MV2yNVU{OzF7NR?=
MCF7S MXjGeY5kfGmxbjDBd5NigQ>? MWixxsDPxE1? NFTsXVE4KGR? MmniZZR1\W63YYTld{B1fW2xcoPwbIVz\SCob4LtZZRqd25iYX7kJJBzd2yrZnXyZZRqd25? MWOyNVU{OzF7NR?=
MCF7S M2XWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H2W|AvPS9zIN88US=> M2KzN|ch\A>? M3zQXWROW09? M{S5NIRm[3KnYYPld{Bk\WyuIHX4dIFve2mxbh?= NHL0Z|YzOTV|M{G5OS=>
T47D  MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrw[Fg1KG6P NIr3SFY1OCCq M1XLdJN2eHC{ZYPz[ZMh[2WubDDndo94fGhibX;k[ZJifGWueR?= MX[yNVQ5ODN7MR?=
BT474  MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHsOZgzPCCwTR?= M17nOlQxKGh? MnrVd5VxeHKnc4Pld{Bk\WyuIHfyc5d1cCCvb3TldoF1\Wy7 Moi0NlE1QDB|OUG=
T47D  M4K4RmZ2dmO2aX;uJGF{e2G7 M1HlUVExKG6P NYHCcItLPDBiaB?= NGDXVZJld3ewcnXneYxifGW|IFXS{tEheHKxdHXpci=> NXvz[olvOjF2OECzPVE>
BT474  Mn[wSpVv[3Srb36gRZN{[Xl? M13YcVExKG6P MW[0NEBp NF7TPWNld3ewcnXneYxifGW|IFXS{tEheHKxdHXpci=> NFz0V|AzOTR6MEO5NS=>
MCF7 MkPNSpVv[3Srb36gRZN{[Xl? Mn3xNVAxKG6P NULRNFcxPyCm NF3adGVz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 NYTtfVg3OjF|OU[wPVQ>
T47D  NGS3bWhHfW6ldHnvckBCe3OjeR?= MVixNFAhdk1? MniwO{Bl NF22N2Vz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 NHTDNpkzOTN7NkC5OC=>
BT474  M{PNSGZ2dmO2aX;uJGF{e2G7 MoPLNVAxKG6P MVu3JIQ> NGSxcWZz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 NGf3bIUzOTN7NkC5OC=>
MDAMB361 Mo\LSpVv[3Srb36gRZN{[Xl? M4roO|ExOCCwTR?= M3jWSVch\A>? MlzSdoVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> M2DhVVIyOzl4MEm0
MCF7 NF60bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO1NE4xOS1zIN88US=> MVG3JIQ> MnKzdoVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 NVfkfHVOOjF|OU[wPVQ>
T47D  NFXJdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPFcm5HOC5yMT2xJO69VQ>? MkDqO{Bl NH3PTlRz\WS3Y3XzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M{nRRlIyOzl4MEm0
BT474  NFy1ZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonjNE4xOS1zIN88US=> MmjnO{Bl MX\y[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? MU[yNVM6PjB7NB?=
MDAMB361 M33qTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPlbWlrOC5yMT2xJO69VQ>? MWe3JIQ> MoTMdoVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M2nIZlIyOzl4MEm0
MCF7 NGfze4VHfW6ldHnvckBCe3OjeR?= MWCxNFAhdk1? NHuyVlY4KGR? MnX4bY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= MnjyNlE{QTZyOUS=
T47D  Moj1SpVv[3Srb36gRZN{[Xl? NEL2XYsyODBibl2= NVXtb491PyCm MYfpcoR2[2W|IH;mJGVz[kJ|IHHu[EBGemKENDDy[YNmeHSxcjDlfJBz\XO|aX;uJIFv\CC|aXfuZYxtcW6p M{PSeFIyOzl4MEm0
BT474  NXLrNVRVTnWwY4Tpc44hSXO|YYm= M1vM[lExOCCwTR?= NGW1NZQ4KGR? NFXnWpNqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n M1y3O|IyOzl4MEm0
MDAMB361 M2q5bmZ2dmO2aX;uJGF{e2G7 MUGxNFAhdk1? M33iUlch\A>? MmPybY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= NWTobHg2OjF|OU[wPVQ>
MCF7 NWrBeW8zTnWwY4Tpc44hSXO|YYm= NWnlT5Q{OTBibl2= M4Tqelk3KGh? NHzPepRld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc47DqA>? M4rZO|IyOzd6M{Oz
MDA-MB-231 NIjOV4RHfW6ldHnvckBCe3OjeR?= NVq4XYY3OTBibl2= MWW5OkBp NGf4NpRld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc47DqA>? NEXWWI4zOTN5OEOzNy=>
SK-BR-3 M2jxUGZ2dmO2aX;uJGF{e2G7 NH25Z2MyOCCwTR?= MnLnPVYhcA>? MXvkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> MViyNVM4QDN|Mx?=
MCF-7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNFAhdk1? MlrnO|IwQTZiaB?= NEjufotk[XW|ZYOgZ4VtdCCleXPs[UBienKnc4S= MXWyNVI6QTh4Mh?=
MMQ MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHxcHhlOC5yMEitOlI2KG6P M2nZWlczKGh? M4HUeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkjhNlA4ODB5NUW=
MMQ MV;GeY5kfGmxbjDBd5NigQ>? MkP5NE4xODhvNkK1JI5O Mn\XO|IhcA>? M1LEbIlvcGmkaYTzJHBTVCC|ZXPy[ZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHfHcnkzODdyMEe1OS=>
MMQ M1HQS2Z2dmO2aX;uJGF{e2G7 MlHaNE4xPC14MkWgcm0> MXq3NkBp MlrkbY5pcWKrdIOgSXLPuSCneIDy[ZN{cW:w NH3oVGUzODdyMEe1OS=>
MMQ NWLEXlhYTnWwY4Tpc44hSXO|YYm= NF7tOG4xNjB2LU[yOUBvVQ>? NELqNXA4OiCq M3TZdZVxemWpdXzheIV{KFSJRt8yN{BidmRiVFfG{tJTUUliZYjwdoV{e2mxbh?= MV2yNFcxODd3NR?=

... Click to View More Cell Line Experimental Data

In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+95% Corn oil
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01797120 Active, not recruiting Metastatic Breast Cancer PrECOG, LLC.|Novartis May 31, 2013 Phase 2
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT03024580 Not yet recruiting Breast Neoplasm Instituto Nacional de Cancer, Brazil|Cancer Research UK Cambridge Institute March 2017 Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3
NCT02983604 Recruiting Advanced Estrogen Receptor Positive HER2- Breast Cancer Gilead Sciences January 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID